KMT2A and B-cell chronic lymphocytic leukemia: Indeed, LCK over-activation has been found to correlate with poor response to treatment in pediatric BCP-ALL patients, [12] MLL-rearranged ALL [13] and in chronic lymphoblastic leukemia (CLL), [14, 15] thus proposing LCK activation as a putative marker for glucocorticoid resistance.